Drugs / SARS-CoV
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00533741 | ? → Jan 2012 | severe acute respiratory syndrome | National Institute of Allergy and Infectious Diseases (NIAID) | Withdrawn | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SARS-CoV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00533741 ↗ |
| Known as | SARS Coronavirus | “Phase I, Double-Blinded, Placebo-Controlled Dosage Escalation Study of the Safety and Immunogenicity of Adjuvanted and Non-Adjuvanted Inactivated SARS Coronavirus (SARS-CoV)...” NCT00533741 ↗ |
| Modality | Vaccine | “Whole-virus vaccine, grown in certified Vero cells and doubly inactivated by treatment with formalin and ultraviolet light (UV).” NCT00533741 ↗ |
| Route | Intramuscular | “administered by the Intramuscular Route” NCT00533741 ↗ |